Mark Melville

Mark Melville has over 20 years of experience in the biopharmaceutical industry. Mark is currently the Vice President of CMC, Biologics at Cullinan Oncology, where they oversee the development and manufacture of biologics. Prior to this, from 2016 to 2020, Mark served as the Senior Director of CMC at Corvidia Therapeutics, where they were responsible for the development and manufacture of the biologics pipeline. Mark managed a network of contract manufacturing and testing labs to bring programs from early development to clinical manufacturing.

From 2012 to 2016, Mark was the Sr. Director of Bioprocess Development at EPIRUS Biopharmaceuticals, leading a development team that managed a global network of contract manufacturers and testing labs. Mark contributed to regulatory filings, participated in due diligence operations, and served as a technical leader in strategic partnerships.

Mark also worked at Percivia from 2011 to 2012 as the Director of Cell Line Generation and Upstream Processing. Mark led the development of a platform to support a pipeline of biosimilars with aggressive timelines and deliverables.

Prior to that, from 2002 to 2011, Mark held various roles at Pfizer, including Senior Principal Scientist and Senior Research Scientist II. Mark focused on cell line and process development for the drug development pipeline.

Mark started their career as a Postdoctoral Fellow at Stanford University from 1998 to 2002.

Mark Melville obtained their PhD in Microbiology from the University of Washington, where they studied from 1992 to 1998.